Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: Induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death

British Journal of Haematology

Volumn 130, Issue 4, 2005, Pages 501-510

  Georgakis, Georgios V ^b   Li, Yang ^b   Humphreys, Robin ^c   Andreeff, Michael ^b   O'Brien, Susan ^b   Younes, Mamoun ^d   Carbone, Antonino ^e   Albert, Vivian ^c   Younes, Anas ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c GLAXOSMITHKLINE   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

Apoptosis; Bortezomib; Hodgkin lymphoma; Leukaemia

Indexed keywords

BORTEZOMIB; CASPASE 8; DEATH RECEPTOR 4; DEATH RECEPTOR 5; DOXORUBICIN; FLICE INHIBITORY PROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HGS ETR1; MONOCLONAL ANTIBODY HGS ETR2; PROCASPASE 8; PROTEIN BAX; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; PYRAZINE DERIVATIVE; TNFRSF10A PROTEIN, HUMAN; TNFRSF10B PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL DEATH; CONTROLLED STUDY; DRUG ACTIVITY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; LYMPHOMA CELL; LYMPHOMA CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR; ANALYSIS OF VARIANCE; CELL CULTURE; CELL PROLIFERATION; COMPARATIVE STUDY; DRUG EFFECT; DRUG POTENTIATION; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOLOGY; LYMPHOMA; NONPARAMETRIC TEST; PATHOLOGY; TUMOR CELL LINE;

ANALYSIS OF VARIANCE; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; BORONIC ACIDS; CELL LINE, TUMOR; CELL PROLIFERATION; DOXORUBICIN; DRUG SYNERGISM; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; LYMPHOMA; PYRAZINES; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECEPTORS, TUMOR NECROSIS FACTOR; STATISTICS, NONPARAMETRIC; TUMOR CELLS, CULTURED;

EID: 24944458177     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2005.05656.x     Document Type: Article

References (29)

1. Almasan A. Ashkenazi A. ( 2003) Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine and Growth Factor Reviews, 14, 337 348.
2. Amin H.M. McDonnell T.J. Medeiros L.J. Rassidakis G.Z. Leventaki V. O'Connor S.L. Keating M.J. Lai R. ( 2003) Characterization of 4 mantle cell lymphoma cell lines. Archives of Pathology and Laboratory Medicine, 127, 424 431.
3. Ashkenazi A. ( 2002) Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nature Reviews Cancer, 2, 420 430.
4. Bhardwaj A. Aggarwal B.B. ( 2003) Receptor-mediated choreography of life and death. Journal of Clinical Immunology, 23, 317 332.
5. Chawla-Sarkar M. Bae S.I. Reu F.J. Jacobs B.S. Lindner D.J. Borden E.C. ( 2004) Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell Death and Differentiation, 11, 915 923.
6. Chou J. Chou T.C. ( 1987) Dose Effect Analysis with Microcomputers: Quantitation of ED50, LD50, Synergism, Antagonism Low-dose Risk, Receptor-ligand Binding and Enzyme Kinetics. Manual and Software. Calcusyn-Biosoft, Cambridge, UK.
7. Clodi K. Wimmer D. Li Y. Goodwin R. Jaeger U. Mann G. Gadner H. Younes A. ( 2000) Expression of tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptors and sensitivity to TRAIL-induced apoptosis in primary B-cell acute lymphoblastic leukaemia cells. British Journal of Haematology, 111, 580 586.
8. Clodi K. Asgari Z. Younes M. Palmer J.L. Cabanillas F. Carbone A. Andreeff M. Younes A. ( 2002) Expression of CD40 ligand (CD154) in B and T lymphocytes of Hodgkin disease: potential therapeutic significance. Cancer, 94, 1 5.
9. Deng Y. Lin Y. Wu X. ( 2002) TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO. Genes and Development, 16, 33 45.
10. Dobson C. Edwards B. Main S. Minter R. Williams L. Salcedo T. Choi G. Albert V. Vaughan T. ( 2002) Generation of Human Therapeutic Anti-TRAIL-R1 Agonistic Antibody by Phage Display. Proceedings of the American Association for Cancer Research, Vol. 43, AACR, San Francisco, CA, USA, p. 579 ( no. 2869).
11. Drexler H.G. ( 1993) Recent results on the biology of Hodgkin and Reed-Sternberg cells: II. Continuous cell lines. Leukemia and Lymphoma, 9, 1 25.
12. Fiumara P. Snell V. Li Y. Mukhopadhyay A. Younes M. Gillenwater A.M. Cabanillas F. Aggarwal B.B. Younes A. ( 2001) Functional expression of receptor activator of nuclear factor kappaB in Hodgkin disease cell lines. Blood, 98, 2784 2790.
13. Fulda S. Meyer E. Debatin K.M. ( 2002) Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Oncogene, 21, 2283 2294.
14. Green D.R. ( 2000) Apoptotic pathways: paper wraps stone blunts scissors. Cell, 102, 1 4.
15. Griffith T.S. Lynch D.H. ( 1998) TRAIL: a molecule with multiple receptors and control mechanisms. Current Opinion in Immunology, 10, 559 563.
16. Ichikawa K. Liu W. Zhao L. Wang Z. Liu D. Ohtsuka T. Zhang H. Mountz J.D. Koopman W.J. Kimberly R.P. Zhou T. ( 2001) Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nature Medicine, 7, 954 960.
17. Johnson R. Huang X. Fiscella M. Cole C. Pukac L. Von Kerczek A. Humphreys R. Grzegorzewski K. Gallant G. Albert V. ( 2003) Human agonistic anti-TRAIL receptor antibodies, HGS-ETR1 and HGS-ETR2, induce apoptosis in diverse hematological tumor lines. Blood, 102 (Abstract 3316).
18. Lamothe B. Aggarwal B.B. ( 2002) Ectopic expression of Bcl-2 and Bcl-xL inhibits apoptosis induced by TNF-related apoptosis-inducing ligand (TRAIL) through suppression of caspases-8, 7, and 3 and BID cleavage in human acute myelogenous leukemia cell line HL-60. Journal of Interferon and Cytokine Research, 22, 269 279.
19. Lee S.H. Shin M.S. Kim H.S. Lee H.K. Park W.S. Kim S.Y. Lee J.H. Han S.Y. Park J.Y. Oh R.R. Kang C.S. Kim K.M. Jang J.J. Nam S.W. Lee J.Y. Yoo N.J. ( 2001) Somatic mutations of TRAIL-receptor 1 and TRAIL-receptor 2 genes in non-Hodgkin's lymphoma. Oncogene, 20, 399 403.
20. Munshi A. Pappas G. Honda T. McDonnell T.J. Younes A. Li Y. Meyn R.E. ( 2001) TRAIL (APO-2L) induces apoptosis in human prostate cancer cells that is inhibitable by Bcl-2. Oncogene, 20, 3757 3765.
21. Pitti R.M. Marsters S.A. Ruppert S. Donahue C.J. Moore A. Ashkenazi A. ( 1996) Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. The Journal of Biological Chemistry, 271, 12687 12690.
22. Pukac L. Kanakaraj P. Humphreys R. Alderson R. Bloom M. Sung C. Riccobene T. Johnson R. Fiscella M. Mahoney A. Carrell J. Boyd E. Yao X.T. Zhang L. Zhong L. von Kerczek A. Shepard L. Vaughan T. Edwards B. Dobson C. Salcedo T. Albert V. ( 2005) HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. British Journal of Cancer, 92, 1430 1441.
23. Salcedo T. Alderson R. Basu S. Beatty S. Choi G. Corcoran M. Halpern W. Gentz S. Gregorio T. Grzegorzewski K. Kanakaraj P. Mahoney A. McCormick K. Miao Y. Moody G. Ourmanova M. Patel V. Pukac L. Riccobene T. Roschke V. ( 2002) TRM-1, a Fully Human TRAIL-R1 Agonistic Monoclonal Antibody, Displays in vitro and in vivo Anti-tumor Activity. Proceedings of the American Association for Cancer Research, Vol. 43, San Francisco, CA, USA, p. 586 ( no. 4240).
24. Snell V. Clodi K. Zhao S. Goodwin R. Thomas E.K. Morris S.W. Kadin M.E. Cabanillas F. Andreeff M. Younes A. ( 1997) Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies. British Journal Haematology, 99, 618 624.
25. Wiley S.R. Schooley K. Smolak P.J. Din W.S. Huang C.P. Nicholl J.K. Sutherland G.R. Smith T.D. Rauch C. Smith C.A. Goodwin R.G. ( 1995) Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity, 3, 673 682.
26. Younes A. Kadin M.E. ( 2003) Emerging applications of the tumor necrosis factor family of ligands and receptors in cancer therapy. Journal of Clinical Oncology, 21, 3526 3534.
27. Zhao S. Asgary Z. Wang Y. Goodwin R. Andreeff M. Younes A. ( 1999) Functional expression of TRAIL by lymphoid and myeloid tumour cells. British Journal Haematology, 106, 827 832.
28. Zheng B. Fiumara P. Li Y.V. Georgakis G. Snell V. Younes M. Vauthey J.N. Carbone A. Younes A. ( 2003) MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival. Blood, 102, 1019 1027.
29. Zheng B. Georgakis G.V. Li Y. Bharti A. McConkey D. Aggarwal B.B. Younes A. ( 2004) Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-κ B mutations or activation of the CD30, CD40, and RANK receptors. Clinical Cancer Research, 10, 3207 3215.